Contributions
Abstract: EP1634
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Background: Multiple sclerosis (MS) is a chronic disease with a variety of affected functional systems. Treatment strategies primarily aiming at improving long-term outcomes for patients with MS need to consider changes in the course of the disease from the patient's and physician's perspective.
Goals: To compare the course of different domains of the physician-based EDSS and patient-based UNDS over time.
Methods: In a multicenter study, 171 patients with relapsing-remitting multiple sclerosis (RRMS) were followed over up to two years. As part of a larger assessment, the UK (Guy´s) Neurological Disability Scale (UKNDS) and the Expanded Disability Status Scale (EDSS) were applied at baseline and every 3 months. Data were analyzed via Generalized Linear Mixed Models. Values are presented as mean ± SE.
Results: Estimates of EDSS were stable (2.5) in the study population over the course of two years. Over time, patients showed no significant change of disability in any sub domains of the UNDS and EDSS, i.e. in the areas motor function, cognition, mood, fatigue, visus, speech and swallowing, bladder and bowel, sensitivity and pain, sexuality. EDSS score remained stable but the UNDS sum score presented significant changes over time (p=.020), by age (p< .001), as well as an interaction between time and age (p=.032) and between time and gender (p=.018). Further, age, and to some extend gender, had an effect on all sub scores of the EDSS and UNDS in favor of younger patients and male patients.
Conclusions: After two years, patient-reported disability domains did not differ from physicians' EDSS assessment. Only the sum score of the UNDS was able to differentiate courses of the disease over time in a stable population at the early stage of disease.
Disclosure: M. Wunderlich: Nothing to disclose.
R. Haase has received travel grants from Teva.
C. Heesen has received research grant as well as speaker honoraries from the following companies: Biogen, MerckSerono, Novartis, Roche and Teva.
M. Berghoff has received research grant as well as speaker honoraries from the following companies: Biogen, MerckSerono, Novartis, Roche and Teva.
F. Paul serves on the scientific advisory board for Novartis; received speaker honoraria and travel funding from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is an academic editor for PLoS ONE; is an associate editor for Neurology® Neuroimmunology & Neuroinflammation; consulted for SanofiGenzyme, Biogen Idec, MedImmune, Shire, and Alexion; and received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, and National Multiple Sclerosis of the USA. A.U. Brandt served on the scientific advisory board for Biogen; received travel funding and/or speaker honoraria from Novartis and Biogen; has patents pending from method and system for optic nerve head shape quantification, perceptive visual computing based postural control analysis, multiple sclerosis biomarker, and perceptive sleep motion analysis; has consulted for Nexus and Motognosis; and received research support from Novartis Pharma, Biogen Idec, BMWi, BMBF, and Guthy Jackson Charitable Foundation. Go to Neurology.org/nn for full disclosure forms.
U. Zettl has received research grant as well as speaker honoraries from the following companies: Biogen, MerckSerono, Novartis, Roche and Teva.
M. Marziniak has received research grant as well as speaker honoraries from the following companies: Biogen, MerckSerono, Novartis, Roche and Teva.
K. Angstwurm has received travel support from the following companies: BayerSchering, Biogen, MerckSerono, Novartis, Roche and Teva.
J. P. Stellmann has received research grant as well as speaker honoraries from the following companies: Biogen, MerckSerono, Novartis, Roche and Teva.
T. Ziemssen has received research grant as well as speaker honoraries from the following companies: Biogen, MerckSerono, Novartis, Roche and Teva.
Abstract: EP1634
Type: Poster Sessions
Abstract Category: Therapy - Long-term treatment monitoring
Background: Multiple sclerosis (MS) is a chronic disease with a variety of affected functional systems. Treatment strategies primarily aiming at improving long-term outcomes for patients with MS need to consider changes in the course of the disease from the patient's and physician's perspective.
Goals: To compare the course of different domains of the physician-based EDSS and patient-based UNDS over time.
Methods: In a multicenter study, 171 patients with relapsing-remitting multiple sclerosis (RRMS) were followed over up to two years. As part of a larger assessment, the UK (Guy´s) Neurological Disability Scale (UKNDS) and the Expanded Disability Status Scale (EDSS) were applied at baseline and every 3 months. Data were analyzed via Generalized Linear Mixed Models. Values are presented as mean ± SE.
Results: Estimates of EDSS were stable (2.5) in the study population over the course of two years. Over time, patients showed no significant change of disability in any sub domains of the UNDS and EDSS, i.e. in the areas motor function, cognition, mood, fatigue, visus, speech and swallowing, bladder and bowel, sensitivity and pain, sexuality. EDSS score remained stable but the UNDS sum score presented significant changes over time (p=.020), by age (p< .001), as well as an interaction between time and age (p=.032) and between time and gender (p=.018). Further, age, and to some extend gender, had an effect on all sub scores of the EDSS and UNDS in favor of younger patients and male patients.
Conclusions: After two years, patient-reported disability domains did not differ from physicians' EDSS assessment. Only the sum score of the UNDS was able to differentiate courses of the disease over time in a stable population at the early stage of disease.
Disclosure: M. Wunderlich: Nothing to disclose.
R. Haase has received travel grants from Teva.
C. Heesen has received research grant as well as speaker honoraries from the following companies: Biogen, MerckSerono, Novartis, Roche and Teva.
M. Berghoff has received research grant as well as speaker honoraries from the following companies: Biogen, MerckSerono, Novartis, Roche and Teva.
F. Paul serves on the scientific advisory board for Novartis; received speaker honoraria and travel funding from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is an academic editor for PLoS ONE; is an associate editor for Neurology® Neuroimmunology & Neuroinflammation; consulted for SanofiGenzyme, Biogen Idec, MedImmune, Shire, and Alexion; and received research support from Bayer, Novartis, Biogen Idec, Teva, Sanofi-Aventis/Genzyme, Alexion, Merck Serono, German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Arthur Arnstein Foundation Berlin, Guthy Jackson Charitable Foundation, and National Multiple Sclerosis of the USA. A.U. Brandt served on the scientific advisory board for Biogen; received travel funding and/or speaker honoraria from Novartis and Biogen; has patents pending from method and system for optic nerve head shape quantification, perceptive visual computing based postural control analysis, multiple sclerosis biomarker, and perceptive sleep motion analysis; has consulted for Nexus and Motognosis; and received research support from Novartis Pharma, Biogen Idec, BMWi, BMBF, and Guthy Jackson Charitable Foundation. Go to Neurology.org/nn for full disclosure forms.
U. Zettl has received research grant as well as speaker honoraries from the following companies: Biogen, MerckSerono, Novartis, Roche and Teva.
M. Marziniak has received research grant as well as speaker honoraries from the following companies: Biogen, MerckSerono, Novartis, Roche and Teva.
K. Angstwurm has received travel support from the following companies: BayerSchering, Biogen, MerckSerono, Novartis, Roche and Teva.
J. P. Stellmann has received research grant as well as speaker honoraries from the following companies: Biogen, MerckSerono, Novartis, Roche and Teva.
T. Ziemssen has received research grant as well as speaker honoraries from the following companies: Biogen, MerckSerono, Novartis, Roche and Teva.